Study of the sensitivity of clinical strains of the spectrum of opportunistic and pathogenic microorganisms to drugs based on bacteriophages
In 2017, the Department of Microbiology, Virology, and Immunology at the A.A. Bogomolets National Medical University conducted a research project titled "Study of the Sensitivity of Clinical Strains of the Spectrum of Opportunistic and Pathogenic Microorganisms to Bacteriophage-Based Drugs" under the supervision of Academician of the National Academy of Sciences and the National Academy of Medical Sciences of Ukraine, Doctor of Medical Sciences, Professor Vladimir Petrovich Shirobokov.
In an experimental study of the bacteriophage preparations " Intestifag " and " Pyofag ", produced by NeoProbioCare Inc, in relation to reference and clinical isolates of Shigella sonnei, Salmonella typhimurium, Salmonella infantis, Salmonella enteritidis, Proteus mirabilis, Proteus vulgaris, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, the presence of specific activity of these preparations to all groups of used microorganisms of varying degrees of severity was shown.
The drugs under study have been shown to be active against prototype ATCC strains of staphylococci, enterococci, Pseudomonas aeruginosa and E. coli .
The activity of the drugs against clinical isolates of various microorganisms varied. For example, the drugs exhibited pronounced specific bacteriolytic activity against a number of clinical strains of gram-positive cocci (94% of susceptible staphylococci and 47% of enterococci).
Representatives of the Enterobacteriaceae family had different sensitivity, which ranged from 75% (for Salmonella) and 25% (for E. coli and Proteus).
Clinical isolates and museum strains of Pseudomonas aeruginosa were moderately sensitive (specific bacteriolytic activity was manifested in 53.8% of strains) to both drugs.
Thus, the drugs " Intestifag " and " Pyofag " produced by NeoProbioCare Inc. can be considered promising drugs with rapid bactericidal action. Adjusting the drug regimen for E. coli is advisable, given the large number of insensitive clinical isolates of this microbe.
The full text of the research report can be downloaded here: